197 related articles for article (PubMed ID: 35657341)
1. The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.
Shah NJ; Patel VG; Zhong X; Pina L; Hawley JE; Lin E; Gartrell BA; Febles VA; Wise DR; Qin Q; Mellgard G; Joshi H; Nauseef JT; Green DA; Vlachostergios PJ; Kwon DH; Huang F; Liaw B; Tagawa S; Kantoff P; Morris MJ; Oh WK
JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35657341
[TBL] [Abstract][Full Text] [Related]
2. Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis.
Sari Motlagh R; Abufaraj M; Karakiewicz PI; Rajwa P; Mori K; Mun DH; Shariat SF
World J Urol; 2022 Apr; 40(4):907-914. PubMed ID: 34477955
[TBL] [Abstract][Full Text] [Related]
3. Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
Jiménez-Alcaide E; García-Fuentes C; Hernández V; De la Peña E; Pérez-Fernández E; Castro A; Caballero-Perea B; Guijarro A; Llorente C
Prostate; 2021 Dec; 81(16):1349-1354. PubMed ID: 34517429
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.
Davidsson S; Messing Eriksson A; Udumyan R; Swanholm P; Lewin Lundh M; Widing C; Lindlöf C; Fridfeldt J; Andersson SO; Fall K
Prostate; 2023 May; 83(6):555-562. PubMed ID: 36658755
[TBL] [Abstract][Full Text] [Related]
5. Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer.
Huang YB; Li WL; Sun M; Duan X; Wang YT; Zhang LX; Xin ZH; Yun ZF; Fan B; Li XC
Asian J Androl; 2023; 25(3):366-374. PubMed ID: 35915542
[TBL] [Abstract][Full Text] [Related]
6. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
Schmidt AL; Tucker MD; Bakouny Z; Labaki C; Hsu CY; Shyr Y; Armstrong AJ; Beer TM; Bijjula RR; Bilen MA; Connell CF; Dawsey SJ; Faller B; Gao X; Gartrell BA; Gill D; Gulati S; Halabi S; Hwang C; Joshi M; Khaki AR; Menon H; Morris MJ; Puc M; Russell KB; Shah NJ; Sharifi N; Shaya J; Schweizer MT; Steinharter J; Wulff-Burchfield EM; Xu W; Zhu J; Mishra S; Grivas P; Rini BI; Warner JL; Zhang T; Choueiri TK; Gupta S; McKay RR
JAMA Netw Open; 2021 Nov; 4(11):e2134330. PubMed ID: 34767021
[TBL] [Abstract][Full Text] [Related]
7. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC
Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370
[TBL] [Abstract][Full Text] [Related]
8. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).
Montopoli M; Zumerle S; Vettor R; Rugge M; Zorzi M; Catapano CV; Carbone GM; Cavalli A; Pagano F; Ragazzi E; Prayer-Galetti T; Alimonti A
Ann Oncol; 2020 Aug; 31(8):1040-1045. PubMed ID: 32387456
[TBL] [Abstract][Full Text] [Related]
9. Effects of Androgen Deprivation Therapy on COVID-19 in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis.
Karimi A; Nowroozi A; Alilou S; Amini E
Urol J; 2021 Jul; 18(6):577-584. PubMed ID: 34302737
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility to SARS-Cov-2 infection and risk for severe COVID-19 in patients with prostate cancer on androgen deprivation therapy.
Gedeborg R; Loeb S; Styrke J; Kiiski-Berggren R; Garmo H; Stattin P
Int J Cancer; 2022 Dec; 151(11):1925-1934. PubMed ID: 35802468
[TBL] [Abstract][Full Text] [Related]
11.
Smile TD; Tom MC; Halima A; Ciezki JP; Reddy CA; Stephans KL; Mian OY; Zhang RX; Klein EA; Campbell S; Ulchaker J; Angermeier K K; Tendulkar RD
Brachytherapy; 2022; 21(1):85-93. PubMed ID: 34656435
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer.
Gedeborg R; Lindhagen L; Loeb S; Styrke J; Garmo H; Stattin P
Scand J Urol; 2022 Apr; 56(2):104-111. PubMed ID: 34939533
[TBL] [Abstract][Full Text] [Related]
13. Complete androgen blockade vs. medical castration alone as adjuvant androgen deprivation therapy for prostate cancer patients following radical prostatectomy: a retrospective cohort study.
Jin D; Jin K; Chen B; Zhou X; Yuan Q; Zhang Z; Wei Q; Qiu S
Chin Med J (Engl); 2022 Apr; 135(7):820-827. PubMed ID: 35234695
[TBL] [Abstract][Full Text] [Related]
14. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data.
Welén K; Rosendal E; Gisslén M; Lenman A; Freyhult E; Fonseca-Rodríguez O; Bremell D; Stranne J; Balkhed ÅÖ; Niward K; Repo J; Robinsson D; Henningsson AJ; Styrke J; Angelin M; Lindquist E; Allard A; Becker M; Rudolfsson S; Buckland R; Carlsson CT; Bjartell A; Nilsson AC; Ahlm C; Connolly AF; Överby AK; Josefsson A
Eur Urol; 2022 Mar; 81(3):285-293. PubMed ID: 34980495
[TBL] [Abstract][Full Text] [Related]
15. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
[TBL] [Abstract][Full Text] [Related]
16. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
17. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
[TBL] [Abstract][Full Text] [Related]
19. Relationship Between Androgen Deprivation Therapy for Prostate Cancer and Risk of SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis.
Kim DK; Park JJ; Yang WJ; Doo SW; Kim JH
J Korean Med Sci; 2022 Aug; 37(31):e237. PubMed ID: 35942555
[TBL] [Abstract][Full Text] [Related]
20. Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy.
Tully KH; Nguyen DD; Herzog P; Jin G; Noldus J; Nguyen PL; Kibel AS; Sun M; McGregor B; Basaria S; Trinh QD
Eur Urol Oncol; 2021 Feb; 4(1):66-72. PubMed ID: 31624049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]